Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma

Journal of Chemotherapy
Giulia CervettiM Petrini

Abstract

Cladribrine (2-CdA), a purine analogue active on both dividing and resting lymphocytes, plays an important role in the treatment of indolent lymphoproliferative malignancies such as Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Lymphoplasmocytic Lymphoma (LPL), Waldenström's Macroglobulinemia (WM). With the aim of evaluating the efficacy and toxicity of low dose 2-CdA, 15 lymphoplasmocytic lymphoma patients, not eligible for more aggressive or standard therapies, because of age or poor performance status, were treated with the drug at a dose of 5 mg/m2, once a week for six total courses. All patients showed disease progression. Fourteen patients were valuable for response. In eleven out of these 14 (85.7%) disease progression stopped, with 21% having good hematological responses (one CR and two PR). The treatment was generally well tolerated, without serious infectious events. This schedule may be appropriate for the management of patients where the aim of the treatment is control of disease progression.

References

Mar 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosR Alexanian
Mar 10, 1994·The New England Journal of Medicine·A Saven, L Piro
Feb 1, 1993·Annals of Internal Medicine·M A DimopoulosR Alexanian
Jan 1, 1993·Leukemia & Lymphoma·M J KeatingE Estey
May 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L BergmannD Hoelzer
Dec 19, 1998·British Journal of Haematology·E S LiuA Saven
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosM Dalakas

❮ Previous
Next ❯

Citations

May 18, 2011·Current Opinion in Hematology·Catherine ThieblemontJosette Brière

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.